Is IONQ The Next NVIDIA?
Quantum computing startup IonQ (NYSE:IONQ) has seen its stock skyrocket…
Sell
36
BIOA Quote, Financials, Valuation and Earnings
Last price:
$4.04
Seasonality move
:
--
Day range:
$3.88 - $4.06
52-week range:
$2.88 - $26.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.45x
Volume:
141.6K
Avg. volume:
209K
1-year change:
--
Market cap:
$142M
Revenue:
--
EPS (TTM):
-$8.05
Analysts' Opinion
-
Consensus RatingBioage Labs has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 3 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $6.00, Bioage Labs has an estimated upside of 51.52% from its current price of $3.96.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $3.96.
Fair Value
-
According to the consensus of 4 analysts, Bioage Labs has 51.52% upside to fair value with a price target of $6.00 per share.
BIOA vs. S&P 500
-
Over the past 5 trading days, Bioage Labs has underperformed the S&P 500 by -3.79% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bioage Labs does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bioage Labs has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Bioage Labs reported revenues of $1.5M.
Earnings Growth
-
Bioage Labs has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Bioage Labs reported earnings per share of -$0.36.
Enterprise value:
-171.5M
EV / Invested capital:
-0.54x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
3.18x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-1133.43%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $1.5M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -$49.7M | -$81.8M | -$12.8M | -$16.4M | |
| EBITDA | -- | -$57.4M | -$69.5M | -$11.7M | -$12.6M | |
| Diluted EPS | -- | -$3.00 | -$8.05 | -$0.38 | -$0.36 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $178.8M | $324.8M | |
| Total Assets | -- | -- | -- | $179.6M | $343.8M | |
| Current Liabilities | -- | -- | -- | $15.1M | $23.7M | |
| Total Liabilities | -- | -- | -- | $365.1M | $30.7M | |
| Total Equity | -- | -- | -- | -$185.5M | $313.2M | |
| Total Debt | -- | -- | -- | -- | $7.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$43M | -$53.2M | -$15.7M | -$17.4M | |
| Cash From Investing | -- | -$155K | -$78.4M | -- | -$78M | |
| Cash From Financing | -- | $179.4M | $211.7M | $168M | -$1.5M | |
| Free Cash Flow | -- | -$43.2M | -$54M | -$15.7M | -$17.8M | |
BIOA
Sector
Market Cap
$142M
$33.4M
Price % of 52-Week High
14.88%
45.16%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
--
-40%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.00
200-day SMA
Buy
Level
$0.00
Bollinger Bands (100)
Sell
Level
3.78 - 4.86
Chaikin Money Flow
Sell
Level
-6.2M
20-day SMA
Sell
Level
$4.00
Relative Strength Index (RSI14)
Sell
Level
48.42
ADX Line
Sell
Level
17.35
Williams %R
Neutral
Level
-44.2308
50-day SMA
Buy
Level
$3.93
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Sell
Level
-690.3K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
Stock Forecast FAQ
In the current month, BIOA has received 0 Buy ratings 3 Hold ratings, and 1 Sell ratings. The BIOA average analyst price target in the past 3 months is $6.00.
-
Where Will Bioage Labs Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bioage Labs share price will rise to $6.00 per share over the next 12 months.
-
What Do Analysts Say About Bioage Labs?
Analysts are divided on their view about Bioage Labs share price and where it will be in the next 12 months. The majority of analysts rate the stock a Sell. However, a smaller subset of analysts suggest that Bioage Labs is a Buy and believe this share price will drop from its current level to $10.00.
-
What Is Bioage Labs's Price Target?
The price target for Bioage Labs over the next 1-year time period is forecast to be $6.00 according to 4 Wall Street analysts, 0 of them rate the stock a Buy, 1 rates the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is BIOA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bioage Labs is a Hold. 3 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BIOA?
You can purchase shares of Bioage Labs via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bioage Labs shares.
-
What Is The Bioage Labs Share Price Today?
Bioage Labs was last trading at $4.04 per share. This represents the most recent stock quote for Bioage Labs. Yesterday, Bioage Labs closed at $3.96 per share.
-
How To Buy Bioage Labs Stock Online?
In order to purchase Bioage Labs stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for Jun 2
Regeneron Pharmaceuticals [REGN] is up 0.05% over the past day.
Buy
55
RGC alert for Jun 2
Regencell Bioscience Holdings [RGC] is down 19.04% over the past day.
Sell
42
AMBA alert for Jun 2
Ambarella [AMBA] is up 0.93% over the past day.
